Published 3 hours ago • loading... • Updated 3 hours ago

WHO Issues First Guidelines for GLP-1 Obesity Treatments

On Monday, the World Health Organization recommended GLP-1 drugs as a tool to manage obesity in adults, publishing guidance in JAMA defining long-term use as six months or more.
Regulatory approvals, including by the Food and Drug Administration, preceded the guidance drafted by a committee of obesity, pharmacology and public-health experts at the request of WHO member states amid debate in recent years.
GLP-1 drugs work by mimicking a hormone that signals fullness and reduce appetite to help people lose weight, while more than 890 million adults worldwide are obese and obesity causes 3.7 million deaths annually.
The recommendation is conditional, the WHO said, as benefits likely outweigh downsides but more long-term safety and efficacy data, plus lower prices, are needed to address access and pricing concerns.
In the U.S., one in eight adults report currently taking a GLP-1 drug amid the societal shift in obesity framing and WHO urging public-health coordination.

Insights by Ground AI

128 Articles

telex.hu

Lean Left

Who Issues Statement on the Use of Weight Loss Miracle Drugs

GLP-1-type consumer drugs can be used in long-term therapy, but access remains a problem.

10 hours ago

Read Full Article

The Age

Lean Left

The WHO endorses Ozempic and other GLP-1s for obesity. Australia’s PBS doesn’t

The WHO’s announcement came hours after Australia released a safety alert over the potential risk of suicidal thoughts and behaviours for people using the medicines.

12 hours ago·Australia

Read Full Article

Deutschlandfunk

Center

Obesity - Who: Conditional Recommendation for Weight Loss Syringes Ozempic, Wegovy, Saxenda and Others

The WHO has published its first guideline on the use of so-called weight loss shots against obesity.

12 hours ago·Germany

Read Full Article

News

Lean Right

WHO declares obesity a chronic disease, makes historic Ozempic decision

Ozempic-style medications have been endorsed as long-term treatments for obesity under new guidelines released by the World Health Organization (WHO), in a historic move that “recognises that obesity is a chronic disease”.

14 hours ago

Read Full Article

Otago Daily Times

Center

WHO backs Ozempic-type drugs for treating obesity

WHO guidelines said GLP-1 medications such as Ozempic or Wegovy could be used by adults as part of a comprehensive approach to obesity treatment. Photo: Getty Images The World Health Organization has released its first guidelines on the Ozempic-type drugs, conditionally recommending their use for long-term treatment of obesity.

18 hours ago·Otago, New Zealand

Read Full Article